HSBC's base case target suggests 10 per cent upside over the prevailing stock price. Its bull case target suggests 40 per ...

Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...

HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...

The Indian market is expected to trade higher on January 15, supported by positive global cues. Nifty futures gained 0.51% on ...

The Nifty50 had a gap-up opening at 23,216.50 on Tuesday and ended the day at 23,176.05, up 0.39% from Monday's close.

Clearance of Biocon's Malaysia unit puts an end to the drugmaker's regulatory hurdles and opens the door for the approval and ...

Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...

Analysts said that assuming a $700 million market size for gAspart, Biocon can see US sales worth $25 million and $50 million ...

Shares of Biocon surged as much as 5 per cent during the trading session on Monday after the USFDA cleared Malaysia unit to ...

From HCLTech Ltd., PCBL Ltd., and Just Dial Ltd. to IndusInd Bank Ltd., here are the stocks that moved the most.

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400 ...

So, buy-on decline to continue over here, but just for intraday perspective, overall swings will continue and one needs to be ...